Crowdonomics
All companies

MXY Holdings Inc.

Operating

Biotech · Long Beach, CA

Estimated pre-money ⓘ
$172.9M
As of Sep 2022 · from Reg A Offering (2022) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2022
Latest share price
$1.00
Reg A Offering (2022) offering price

Financials

FY2021 · from SEC filings · hover any figure for its source
$12.6M
$1.2M
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited
Income statement
Revenue
$12,634,582
Cost of goods sold
$14,699,033
Gross margin
-16%
Net income
$1,217,016
Balance sheet
Cash
$3,603,710
Accounts receivable
$1,286,036
Total assets
$55,200,152
Long-term debt
$48,187,957
Total liabilities
$54,384,962
Other
Headcount
19

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$172.9M
est. pre-money
Reg A+ · Equity · Sep 2022

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Oct 14, 2022
Series A Preferred Stock · 2.05%Series B Preferred Stock · 0.82%Series C-1 Preferred Stock · 0.51%Series P-1 Stock · 0.26%Series C Preferred Stock · 0.2%Series P-2 Stock · 0.12%Common Stock · 96.0%
ClassOutstandingVotes / shareShare of totalLast price
Series A Preferred Stockpreferred3,550,000—2.05%—
Series B Preferred Stockpreferred1,425,000—0.82%—
Series C-1 Preferred Stockpreferred884,642—0.51%—
Series P-1 Stockpreferred440,846—0.26%—
Series C Preferred Stockpreferred345,242—0.2%—
Series P-2 Stockpreferred211,271—0.12%—
Common Stock166,012,988—96.0%—
Total172,869,989100%

Principal holders% as the filing states it, Oct 14, 2022

  • Lams Holdings, LLC43,600,109 Common Stock22.0%of company
  • Jordan Lams43,600,109 Common Stock22.0%of company
  • D18 Anacapa LLC28,406,131 Common Stock14.4%of company
  • KPM84 LLC23,121,270 Common Stock11.7%of company
  • Kevin Marrone23,121,270 Common Stock11.7%of company
  • Monarch Management Partners, LLC13,858,678 Common Stock7%of company
  • The Parcon-Martin Family Trust10,569,723 Common Stock5.34%of company
  • Billy C. Maddox10,569,723 Common Stock5.34%of company
  • Neil Hammad1,722,468 Common Stock0.87%of company
  • David Hayes956,927 Common Stock0.48%of company
  • Brett Carman861,234 Common Stock0.44%of company

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Sep 2022Closedvia DALMORE GROUP LLC
Raised $0 / $75MEst. pre-money $172.9M

Team

6 people
Jordan Lams
Director, CEO
Brett Carman
Chief Financial Officer
Daniel Weinstein
Chief Development Officer
David Hayes
Chief Legal Officer
Kevin Marrone
Director, Executive Vice President
Neil Hammad
Chief Operating Officer

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

  • Form 1-A-WOct 26, 20220001477932-22-007933
    EDGAR
  • Form QUALIFOct 21, 20229999999994-22-000402
    EDGAR
  • Form 1-A/AOct 14, 20220001477932-22-007638
    EDGAR
  • Form 1-ASep 9, 20220001477932-22-006776
    EDGAR
Source: SEC EDGARCIK 0001919861DEShare price $1.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.